Navigation Links
High blood pressure, low energy -- a recipe for heart failure
Date:8/13/2007

Aug. 10, 2007 -- Many people with long-standing high blood pressure develop heart failure. But some don't. Daniel P. Kelly, M.D., and colleagues at Washington University School of Medicine in St. Louis and other institutions are trying to figure out what could explain that difference.

Their latest research reveals that impaired energy production in heart muscle may underlie heart failure in some hypertensive patients. The researchers assert that a molecular factor involved in maintaining the heart's energy supply could become a key to new approaches to prevent or treat heart failure.

The molecular factor, a protein called estrogen-related receptor alpha (ERR alpha), helps the heart keep up with energy-draining conditions like high blood pressure, which makes the heart work harder to pump blood. In the July issue of Cell Metabolism, Kelly and his colleagues report that mice born without any ERR alpha developed symptoms of heart failure when their hearts were forced to pump against high pressure. The hearts of normal mice took that pressure overload in stride and stayed healthy. Those contrasting outcomes suggest that heart health greatly depends on ERR alpha.

"The stress of a cardiac pressure overload asks heart muscle to manufacture more high energy compounds, and without ERR alpha, they can't do it," explains Kelly, the Tobias and Hortense Lewin Professor and Chief of the Cardiovascular Division. "You could say that in high blood pressure conditions, the heart fails because it becomes energy starved. And if you could feed the heart by using a drug that enhances ERR, for example you might enable the heart to better keep pace with its energy requirements."

Although preventions and treatments are now available for heart failure due to high blood pressure, almost all of those drugs act outside the heart by dilating blood vessels throughout the body to reduce resistance. In the future, doctors might look for diminished energy capacity in the hearts of hypertensive patients and administer drugs that would rev up energy-producing pathways such as those controlled by ERR alpha, according to Kelly. Kelly is also director of the Center for Cardiovascular Research and professor of medicine, of pediatrics and of molecular biology and pharmacology.

ERR alpha sits in the nucleus of cells and senses how much energy is needed. When a heart cell finds itself short on energy, say because it's being called on to contract harder or faster, its ERR is activated by an inducible co-activator called PGC-1, turning on genes that increase the heart's capacity to burn fats for fuel.

In mice that lacked ERR alpha and that were exposed to pressure overload, the researchers observed signs of early heart failure: the mouse hearts dilated and didn't contract effectively, the heart walls thinned, fibrous connective tissue accumulated and some heart cells died. They also saw that the hearts had depleted fuel reserves.

Kelly indicates that these studies show for the first time that changes in the ability of the heart to produce energy lead to heart failure in some cases. "ERR and some of its partners in the cell are a little like puppeteers controlling the expression of genes for energy production," Kelly says. "This research is especially exciting because ERR can be activated with small compounds, making it a good target for drugs."


'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Related biology news :

1. Placenta Is A Rich Source Of Blood Stem Cells
2. White blood cell waste disposal system plays critical regulatory role
3. Epstein-Barr virus protein crucial to its role in blood cancers
4. New insight into regulation of blood stem cells
5. Infants With Rare Genetic Disease Saved by Cord Blood Stem Cells
6. White Blood Cell Waste Disposal System Plays Critical Regulatory Role
7. Mystery Blood Vessel Disorder Implicated In Mini Strokes
8. Nano-bumps could help repair clogged blood vessels
9. First technology to remove prions that cause vCJD from blood launched
10. Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells
11. Breakthrough isolating embryo-quality stem cells from blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2016)...  xG Technology, Inc. ("xG" or the "Company") (Nasdaq: ... for use in challenging operating environments, announced its results ... will hold a conference call to discuss these results ... (details below). Key Recent Accomplishments ... agreement to acquire Vislink Communication Systems. The purchase is ...
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... finalists in the World Technology Awards. uBiome is one of just six company ... all categories. , In addition to uBiome, companies nominated as finalists in this ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. (OTCQB: ... focused on developing and commercializing products to treat rare ... today that it will be hosting an Investor Webcast ... on the origins of innate defense regulators (IDRs) as ... of oral mucositis and the recently announced and published ...
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, ... purpose of the trial was to determine the safety, antitumor activity, and recommended ...
Breaking Biology Technology: